Abstract:Background: Substantial heterogeneity of motor symptoms in Parkinson's disease (PD) poses a challenge to disease prediction. Objectives: The aim of this study was to construct a nomogram model that can distinguish different longitudinal trajectories of motor symptom changes in early-stage PD patients. Methods: Data on 90 patients with 5-years of follow-up were collected from the Parkinson's Progression Marker Initiative (PPMI) cohort. We used a latent class mixed modeling (LCMM) to identify distinct progression patterns of motor symptoms, and backward stepwise logistic regression with baseline information was conducted to identify the potential predictors for motor trajectory and to develop a nomogram. The performance of the nomogram model was then evaluated using the optimism-corrected C-index for internal validation, the area under the curve (AUC) of the receiver operating characteristic (ROC) curve for discrimination, the calibration curve for predictive accuracy, and decision curve analysis (DCA) for its clinical value. Results: We identified two trajectories for motor progression patterns. The first, Class 1 (Motor deteriorated group), was characterized by sustained, continuously worsening motor symptoms, and the second, Class 2 (Motor stable group), had stable motor symptoms throughout the follow-up period. The best combination of 7 baseline variables was identified and assembled into the nomogram: Scopa-AUT [odds ratio (OR), 1.11; p = 0.091], Letter number sequencing (LNS) (OR, 0.76; p = 0.068), the asymmetry index of putamen (OR, 0.95; p = 0.034), mean caudate uptake (OR, 0.14; p = 0.086), CSF pTau/alpha-synuclein (OR, 0.00; p = 0.011), CSF tTau/A beta (OR, 25434806; p = 0.025), and the index for diffusion tensor image analysis along the perivascular space (ALPSindex) (OR, 0.02; p = 0.030). The nomogram achieved good discrimination, with an original AUC of 0.901 (95% CI, 0.813-0.989), and the bias-corrected concordance index (C-index) with 1,000 bootstraps was 0.834. The calibration curve and DCA also suggested both the high accuracy and clinical usefulness of the nomogram, respectively. Conclusions: This study proposes an effective nomogram to predict different motor progression patterns in earlystage PD. Furthermore, the imaging biomarker indicating glymphatic function could be an independent predictive factor for PD motor progression.

Artificial neural network predicts sex differences of patients with advanced Parkinsons disease under Levodopa-Carbidopa Intestinal gel

An Artificial Neural Network Predicts Gender Differences of Motor and Non-Motor Symptoms of Patients with Advanced Parkinson's Disease under Levodopa-Carbidopa Intestinal Gel

Application of Machine Learning in a Parkinson's Disease Digital Biomarker Dataset Using Neural Network Construction (NNC) Methodology Discriminates Patient Motor Status

Morphologic brain network predicts levodopa responsiveness in Parkinson disease

Machine Learning-Based Prediction of Impulse Control Disorders in Parkinson’s Disease From Clinical and Genetic Data

Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson's Disease: A Retrospective Analysis.

Machine Learning Model Based on Sex Subgroup for Improving Parkinson's Disease Diagnosis

Machine Learning-Based Personalized Subthalamic Biomarkers Predict ON-OFF Levodopa States in Parkinson Patients.

Prediction of motor and non-motor Parkinson’s disease symptoms using serum lipidomics and machine learning: a 2-year study

Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers

Sex-Specific Imaging Biomarkers for Parkinson's Disease Diagnosis: A Machine Learning Analysis

Sex-Specific Imaging Biomarkers for Parkinson’s Disease Diagnosis: A Machine Learning Analysis

Wearable sensor devices can automatically identify the ON-OFF status of patients with Parkinson's disease through an interpretable machine learning model

Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson’s Disease

Motor Progression Phenotypes in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Glymphatic System Imaging Biomarkers.

Multivariable Clinical-Genetic Model for Predicting Dyskinesia in Early-Onset Parkinson's Disease

Motor Progression Marker for Newly Diagnosed Drug‐naïve Patients with Parkinson's Disease: A Resting‐state Functional MRI Study

Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease

Machine learning based risk prediction for Parkinson's disease with nationwide health screening data

Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease

Predicting Parkinson's disease evolution using deep learning